PTC/SB/08a (08-03)
Approved for use through 97/31/2006, ONE 0651-0231
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number			
	Filing Date			
	First Named Inventor Hajin		me KANDO	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	36856.1461	

U.S.PATENTS							Remove				
Examiner Initial*	Cite No			Releva	,Columns,L ant Passag s Appear						
	1										
If you wis	h to a	dd additional U.S. Pate	nt citatio	n inform	ation p	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	umber Kind Code ¹ Publication Name of Patentee or Application of cited Document			Releva	,Columns,l int Passag s Appear				
	1										
If you wis	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	lease click the Ad	d button	Add		
				FORE	GN PA	TENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Countr Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colu where Rele Passages of Figures Ap	vant or Relevant	
	1	10-233647	JP		A	1998-09-02					V
	2	10-247835	JP		A	1998-09-14					Z
	3	09-107264	JP		A	1997-04-22					V

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor Hajim		ne KANDO
Art Unit		
Examiner Name		
Attorney Docket Number		36856.1461

	4	2004/095699	wo	A1	2004-11-04			V
	5	98/51011	wo	A1	1998-11-12			Z
	6	2003-114592	JP	A1	2003-04-18			V
If you wisl	h to ac	dd additional Foreign P				ease click the Add butto		
			NON-PATEN	NT LITE	RATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when approp tate, pages(s), volume-is		T5
	1	International Search Report issued in the corresponding International Application No. PCTI/IP2004/019551, mailed on May 17, 2005.						
	2	CHUJO et al., "Piezoelectric Boundary Wave in a Substrate with a Layered Structure," Research Institute of Electrical Communication, 1980, pp. 21-28.						
	3	SHIMIZU, "SAW Propagation Characteristics on LITeO3 With Arbitrary Cut," Tokyo Institute of Technology, Tokyo, 1980, pp. 140-145, vol. 36, no. 3.						
	SHIBAYAMA, "Acoustic Wave Device Technology Handbook," The 150th Committee on Acoustic Wave Device Technology, Japan Society for the Promotion of Science, November 30, 1991, p. 549.							V
	5	CAMPBELL et al., "A Method for Estimating Optimal Crystal Cuts and Propagation Directions for Excitation of Pezcelectric Guriace Waves," IEEE Transactions on Sonics and Ultrasonics, October 1965, pp. 209-217, Volume SU-15, No. 4.						
	6	YAMANCUCHI et al., "Piezoelectric Acoustic Boundary Waves Propagaling Along the Interface Between SIG2 and LITaG3," IEEE Transactions on Sonics and Ultrasonics, November, 1978, pp. 384-389, Volume SU-25, No. 6.						

	Application Number		
NEODMATION DIOOLOGUEE	Filing Date		
NFORMATION DISCLOSURE STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	First Named Inventor	Hajin	ne KANDO
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	36856.1461

7 SHIBAYAMA, "Engineering of Surface Acoustic Wave," Institute of Electronics and Communication Engineers of Japan, November 15, 1983, pp. 56-58. 7

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

See Kins Code of USPTO Patient Documents at smeruLBETD,GD(v or MEEP 9910.4. ² Enter office that issued the document, by the Novelets code (WIPO Standard ST.3.) ² For Juspaces patient colorments, but notices the year of the Emperor many precious be seen all under of the patient colorment, and occurrent the patient occurrent. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if Emplish targuages the relation is databale.

Examiner Signature

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patter office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 155(c) more than three months prior to the filing of the information disclosure statement. Sea 27 CFR 197(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_							
Signature	/Joseph R. Keating #37,368/	Date (YYYY-MM-DD)	2006-07-12				
Name/Print	Joseph R. Keating	Registration Number	37368				

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 GA 37 CFR.

1.14. This collection is estimated to take I hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. O. Box 1430, Alexandriu, V.S. 2213.1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.A. 2213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.